ME 23andMe Holding Co: רווח נקי למניה ב-12 החודשים האחרונים

23andMe Holding Co. (ME) is transforming its business, pivoting from stagnant testing toward drug discovery. The 12-month YoY change in net income per share reflects profitability dynamics, with the current level standing at -56.70. Revenue stability remains moderate as the subscription monetization model evolves. Simultaneously, 23andMe Holding Co. (ME) is implementing ESG standards by utilizing biodegradable packaging and protecting the privacy of genetic data.
ME (23andme.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Minimizing fundamental risks requires selecting assets with sustainable profit dynamics. This indicator measures the annual change in net profit per share over a twelve-month rolling period, excluding quarterly lags. For 23andMe Holding Co. (ME), this metric reflects the monetization efficiency of genetic data and subscription services. By analyzing the 12-month YoY EPS growth chart on GURU.Markets, an investor can discern the actual speed of business scaling. A declining curve signals rising operating expenses.